SCHEMBL7704908

SCHEMBL7704908

CCOC(=O)C(CC)Oc1cc2c(cc1[N+](=O)[O-])CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GALR2 O43603 1/20 0.38
MITF O75030 1/20 0.38
POLB P06746 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HPGD P15428 1/20 0.38
XBP1 P17861 1/20 0.38
CCR6 P51684 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NPC1 O15118 5/20 0.37
RAB9A P51151 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CASP3 P42574 1/20 0.37
ATM Q13315 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
GPR174 Q9BXC1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708269 0.98 ALDH1A1 (0.39) ALDH1A1LMNASMN1; SMN2GALR2MITF
SCHEMBL6999500 0.86 ALDH1A1 (0.42) ALDH1A1LMNASMN1; SMN2GALR2MITF
SCHEMBL6995241 0.84 ALDH1A1 (0.44) ALDH1A1LMNASMN1; SMN2GALR2MITF
SCHEMBL6993182 0.83 ALDH1A1 (0.43) ALDH1A1LMNASMN1; SMN2GALR2MITF
SCHEMBL6994446 0.83 ALDH1A1 (0.43) ALDH1A1LMNASMN1; SMN2GALR2MITF
SCHEMBL6994344 0.83 ALDH1A1 (0.43) ALDH1A1LMNASMN1; SMN2GALR2MITF
SCHEMBL6996661 0.83 ALDH1A1 (0.43) ALDH1A1LMNASMN1; SMN2GALR2MITF
SCHEMBL7704925 0.78 MEN1 (0.40) ALDH1A1POLBNPC1RAB9AL3MBTL1
SCHEMBL10679958 0.76 ALDH1A1 (0.36) ALDH1A1LMNASMN1; SMN2POLBNPC1
SCHEMBL7713466 0.75 MEN1 (0.40) ALDH1A1LMNAPOLBHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed